However, more evidence is needed to clarify their systemic effects and controversial direct hepatic benefits
Tirzepatide , the active ingredient in both Mounjaro and Zepbound is currently being evaluated in phase 3 trials for cardiovascular outcomes in diabetes patients, heart failure with preserved ejection fraction, morbidity and mortality in obesity, and obstructive sleep apnea (OSA)
Many people begin this process by scheduling a weight loss consultation Indianapolis to discuss their health history, treatment goals, and available medical weight management options with an experienced healthcare provider
Our team will guide you based on your goals, whether thats energy, recovery, immunity, general wellness or something else